Gufic Biosciences Ltd. (GUFICBIO) — NSE Stock Analysis

Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic.

Company Overview

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India.

Valuation Snapshot

• Market cap: —
• P/E: —
• P/B: —
• ROE: —

Blanket Finance is not a SEBI-registered investment adviser or research analyst. This content is for educational and informational purposes only.